In-vitro Dissolution: Order and questions [Regulatives / Guidelines]

posted by mittyri  – Russia, 2014-01-22 20:39 (4542 d 22:14 ago) – Posting: # 12230
Views: 10,708

Hi Sireen, Dr_Dan and Helmut!

I would continue this discussion.
According to the chapter 4.2.2
"Similarity of in vitro dissolution should be demonstrated at all conditions within the applied product series, i.e. between additional strengths and the strength(s) (i.e. batch(es)) used for bioequivalence testing."
Do I understand correct the order:
  1. to perform dissolution tests at three different buffers for the BEQ batches of test and reference
  2. to perform dissolution tests at three different buffers for BEQ batch (test) and all additional strengths of test product
    (Linearity of PK is proven)
"It is recommended to use 12 units of the product for each experiment". Why 12? If we obtain results of 6 tablets - isn't it enough for evaluation?
(Our preceding GL states that we could use 6 units only. Now we use EMA GL.)

Is there no need for additional dissolution tests of different strengths of reference product (no need to compare other Reference Batches to the Test Batches)?

What could we do if information is published (not from Originator) about instability of the active substance in one of ph media? Should we check it or refer to the source only?

Kind regards,
Mittyri

Complete thread:

UA Flag
Activity
 Admin contact
23,656 posts in 4,994 threads, 1,570 registered users;
369 visitors (0 registered, 369 guests [including 15 identified bots]).
Forum time: 19:53 CEST (Europe/Vienna)

Try to learn something about everything
and everything about something.    Thomas Henry Huxley

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5